DSIP

The discovery was striking enough that a small wave of clinical interest followed in the late 1970s and early 1980s, mainly in Switzerland and Germany, testing DSIP for insomnia, opioid withdrawal and chronic pain. Then the literature essentially stopped. There has been almost no serious modern research on DSIP for forty years. The peptide sold online today as a sleep aid is being marketed on a body of evidence that is small, old, and largely inconclusive.

DSIP has the unusual distinction of being an "interesting peptide" that the scientific community quietly stopped investigating. After the 1977 isolation, a small group of Swiss and German clinicians ran a handful of trials in the 1980s for insomnia, chronic pain and opioid withdrawal. The headline sleep result, Schneider-Helmert's reports of improved sleep efficiency in chronic insomniacs, was based on small samples (typically 10–20 subjects), some of it cross-over, some of it open-label, with replication attempts producing mixed-to-negative results. The 1984 Larbig chronic-pain pilot was small and inconclusive. The 1998 Backmund opioid-detox trial was open-label without a control arm. By the early 2000s, the literature had effectively ceased: PubMed indexes only a trickle of new DSIP work after 2000, mostly review articles citing the same 1980s primary studies. No DSIP receptor has been identified. No Phase 2/3 trial has ever been registered with the FDA or EMA. No regulator anywhere has approved DSIP for any indication. That 40-year silence is itself the strongest evidence: if the original sleep effect had been real and reproducible, it would not have been left on the shelf. Honest position: an old, unfinished story with a body of small, mostly equivocal trials and no modern confirmation.

There is no approved human protocol for DSIP, so no safe or effective dose has been established by any regulator. The 1980s clinical trials used microgram-to-low-milligram subcutaneous or intravenous doses (often 25–100 µg/kg) administered for short courses, but those studies are not gold-standard trials and the peptide sold online today is not the same regulated material. Online sources describe single-digit milligram subcutaneous injections at bedtime, these regimens are not supported by clinical evidence. A qualified clinician should be consulted before considering any peptide.

Long-term safety in humans is unknown. The 1980s clinical trials reported few short-term adverse events at the doses tested, but those trials were small and short, and modern pharmacovigilance does not exist for DSIP. Reported short-term effects in older studies and in user reports include mild headache, dizziness, and transient injection-site reactions. Because DSIP is sold strictly as a research chemical, batch purity, sterility and dose-by-dose consistency are not regulated, a real safety concern independent of the molecule itself. The pharmacokinetics are also poorly characterised in modern terms: the very short half-life makes pharmacodynamic effects difficult to predict. People who are pregnant, breastfeeding, immunocompromised, taking sedatives or sleep medications, or with significant medical conditions should be especially cautious.